AERPIO PHARMACEUTICALS
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development. Aerpio Pharmaceuticals was founded in 2011 and is based in Cincinnati, Ohio, United States.
AERPIO PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Cincinnati, Ohio, United States
Country:
United States
Website Url:
http://www.aerpio.com
Total Employee:
11+
Status:
Active
Contact:
(513) 985-1924
Total Funding:
107.54 M USD
Technology used in webpage:
Domain Not Resolving SPF IPv6 Cloudflare Hosting Cloudflare DNS MediaElement.js
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Alethia BioTherapeutics
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Araim Pharmaceuticals
Araim Pharmaceuticals is a clinical-stage biotechnology company that offers technology to address injuries and chronic diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
IMMvention Therapeutix
IMMvention Therapeutix is a biotechnology company developing novel small molecule pan-inflammasome inhibitors for inflammatory diseases.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
MSTM
MSTM is an ionization innovation company that develops novel ionization techniques for mass spectrometry.
Phelix Therapeutics
Dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis, and other Fibrotic Diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Athenian Venture Partners
Athenian Venture Partners investment in Venture Round - Aerpio Pharmaceuticals
Kearny Venture Partners
Kearny Venture Partners investment in Venture Round - Aerpio Pharmaceuticals
Triathlon Medical Venture Partners
Triathlon Medical Venture Partners investment in Venture Round - Aerpio Pharmaceuticals
Venture Investors
Venture Investors investment in Venture Round - Aerpio Pharmaceuticals
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - Aerpio Pharmaceuticals
Ally Bridge Group
Ally Bridge Group investment in Venture Round - Aerpio Pharmaceuticals
Satter Investment Management
Satter Investment Management investment in Venture Round - Aerpio Pharmaceuticals
Montrose Capital Partners
Montrose Capital Partners investment in Venture Round - Aerpio Pharmaceuticals
OrbiMed
OrbiMed investment in Venture Round - Aerpio Pharmaceuticals
Athenian Venture Partners
Athenian Venture Partners investment in Venture Round - Aerpio Pharmaceuticals
Newest Events participated
Participated in 2017 CincyTech Big Breakfast + Startup Showcase
on 2017-11-08 as exhibitor
Official Site Inspections
http://www.aerpio.com Semrush global rank: 13.31 M Semrush visits lastest month: 78
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 13.248.213.45
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Aerpio Pharmaceuticals"
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive ...
May 17, 2021 Aerpio, Aadi and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Aerpio in connection …See details»
Aadi Bioscience Announces Closing of Merger with Aerpio …
Aug 26, 2021 Ladenburg Thalmann & Co. Inc. acted as financial advisor to Aerpio for the transaction and Goodwin Procter LLP served as legal counsel to Aerpio. Management and …See details»
Aerpio Pharmaceuticals - Crunchbase Company Profile & Funding
Aerpio Pharmaceuticals is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular …See details»
Corporate Overview - AADI Bio
Stockholders of Aerpio in connection with the proposed transaction. Information about Aerpio’s directors and executive office rs is set forth in Aerpio’s Annual Report on Form 10- K for the …See details»
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive ...
May 17, 2021 About Aerpio Pharmaceuticals Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for …See details»
Aadi Bioscience, Inc. completed the acquisition of Aerpio ...
Aug 25, 2021 In connection with the merger, Aerpio will seek to amend its certificate of incorporation to affect a reverse split of Aerpio Common Stock at a ratio to be determined by …See details»
Aadi Bioscience and Aerpio Pharmaceuticals Close Merger and …
Sep 1, 2021 Aadi Bioscience has closed its previously announced merger with Aerpio Pharmaceuticals and a concurrent $155-million PIPE investment. Aadi Bioscience, a US …See details»
Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive ...
May 18, 2021 The Life Sciences team advised Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO) on its definitive merger agreement with Aadi Bioscience, Inc.. Aerpio is a biopharmaceutical …See details»
Aerpio Company Profile 2024: Valuation, Investors, Acquisition
Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 …See details»
Aadi Bioscience Announces Closing of Merger with Aerpio ... - Avoro
Aug 26, 2021 Ladenburg Thalmann & Co. Inc. acted as financial advisor to Aerpio for the transaction and Goodwin Procter LLP served as legal counsel to Aerpio. Management and …See details»
Aerpio Provides Second Update on Aadi Bioscience Presentation …
Jun 4, 2021 Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which Aerpio believes that …See details»
Aerpio Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Aerpio Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. Aerpio Pharmaceuticals has 5 current employee …See details»
Aadi Bioscience Closes Merger with Aerpio Pharmaceuticals
Aug 27, 2021 Ladenburg Thalmann & Co. Inc. acted as financial advisor to Aerpio for the transaction and Goodwin Procter LLP served as legal counsel to Aerpio. Management and …See details»
Aerpio Pharmaceuticals - Funding, Financials, Valuation & Investors
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment. ... How much funding has this …See details»
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare …
May 27, 2020 Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications.See details»
Aadi Bioscience Announces Closing of Merger with Aerpio …
Aug 26, 2021 Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement. Aadi Bioscience . Thu, Aug 26, 2021, 4:05 PM 10 min read.See details»
Aerpio Pharma shares surge 20% on merger deal with Aadi …
May 17, 2021 On a pro forma basis, Aadi and Aerpio shareholders will own ~66.8% and ~33.2% of the combined company, respectively. The transaction is expected to close in Q3 2021.See details»
Aerpio Reports First Quarter 2021 Financial Results and Provides ...
May 17, 2021 Ended first quarter 2021 with $39.0 million in cash and cash equivalents Subsequent to March 31, 2021, Aerpio entered into an agreement and plan of merger with …See details»
Aerpio Provides Update on Aadi Bioscience Presentation at
May 19, 2021 Information about Aerpio’s directors and executive officers is set forth in Aerpio’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the …See details»